Search

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

16.36 -1.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.48

Max

16.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.1M

37M

Pardavimai

5.5M

83M

P/E

Sektoriaus vid.

6.895

47.946

Pelnas, tenkantis vienai akcijai

0.28

Pelno marža

44.958

Darbuotojai

128

EBITDA

4.8M

55M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+8.76% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

218M

2.1B

Ankstesnė atidarymo kaina

17.51

Ankstesnė uždarymo kaina

16.36

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-09 20:06; UTC

Aurinia Pharmaceuticals Inc shares are advancing, continuing their upward trajectory since Thursday's close, amid generally positive market conditions in the biotechnology sector.

2026-10-08 20:01; UTC

Aurinia Pharmaceuticals Inc shares are advancing, recovering from a mid-morning dip to near the day's high, following a higher trend since Wednesday's close.

2026-10-07 19:45; UTC

Aurinia Pharmaceuticals Inc is trading higher, reaching a peak earlier today, but remains below its 20-day moving average after six consecutive lower closes.

2026-10-06 23:10; UTC

Aurinia Pharmaceuticals Inc. declines in after-market trading, closing at its lowest point of the day and remaining below its 20-day moving average.

2026-10-02 20:07; UTC

Aurinia Pharmaceuticals Inc shares fell, marking a fifth consecutive session of lower closes, and remain significantly below their 20-day moving average.

2026-10-01 22:50; UTC

Declining in after-market, Aurinia marks fourth straight session lower.

2026-09-29 20:07; UTC

Aurinia Pharmaceuticals Inc shares fell, reversing from an earlier rise, and are currently positioned around the midpoint of their one-month trading range.

2026-09-24 20:03; UTC

Aurinia Pharmaceuticals Inc is trading higher amid gains in the Biotechnology sector, remaining above its 20-day moving average and within its one-month range.

2026-09-23 20:07; UTC

Aurinia Pharmaceuticals Inc shares fell sharply, continuing a decline from Tuesday's close amid a broader market trend of lower performance.

2026-09-22 22:01; UTC

Aurinia Pharmaceuticals Inc is declining in after-market trading, influenced by broader market pressures and an unexpected contraction in the U.S. Richmond Fed Manufacturing Index.

2026-09-16 19:22; UTC

News

Aurinia Pharmaceuticals Inc shares are significantly higher after reporting a substantial increase in quarterly revenue and a rise in net income from LUPKYNIS sales.

2026-09-15 19:56; UTC

Aurinia Pharmaceuticals Inc. shares are trading lower amid broader market sentiment influenced by anticipated Federal Reserve rate hikes and rising Treasury yields.

2026-09-14 20:07; UTC

Aurinia Pharmaceuticals shares are higher amid market volatility and inflation concerns ahead of the Federal Reserve's interest rate decision.

2026-09-10 20:06; UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

2026-09-09 20:41; UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

2026-09-08 23:36; UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

2026-09-01 20:08; UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

2026-08-26 20:08; UTC

News

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

2026-08-25 19:36; UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

2026-08-24 22:01; UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

2026-08-21 23:06; UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

2026-08-20 21:46; UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026-08-19 23:02; UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

2026-08-18 19:56; UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

2026-08-17 20:02; UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

2026-08-14 19:26; UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

2026-08-13 19:56; UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

2026-08-11 20:06; UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

2026-08-10 20:06; UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

2026-08-07 19:16; UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

8.76% į viršų

12 mėnesių prognozė

Vidutinis 18 USD  8.76%

Aukščiausias 21 USD

Žemiausias 16 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat